ClinicalTrials.gg
CompletedNCT07158099Updated Aug 24, 2026

Bioequivalence Study of WP205 in Healthy Subjects

A Phase 1 interventional study of Methylconalamin Injection(WP205) and Methylconalamin for Injection in Therapeutic Equivalency, Healthy, sponsored by Wanbangde Pharmaceutical Group Co., LTD. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Wanbangde Pharmaceutical Group Co., LTD · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a single-center, randomized, open-label, two-period, two-sequence, single-dose, crossover bioequivalence trial conducted under fasting conditions in healthy adult volunteers. Participants will be randomized into two sequences (A and B). Each participant will receive a single intramuscular dose of the test or reference formulation according to the assigned sequence, with an adequate washout period between dosing. The primary objective of the study is to evaluate the bioequivalence of the two formulations.

02

Conditions studied

  • Therapeutic Equivalency, Healthy
03

In context

Lead sponsor

Wanbangde Pharmaceutical Group Co., LTD is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects have been fully informed of the study purpose, nature, procedures, and potential adverse reactions, voluntarily agree to participate, and have signed the form prior to any study-related procedures.
  2. Male or female subjects aged 18 years or older, with an appropriate gender distribution.
  3. Body weight: females ≥ 45.0 kg, males ≥ 50.0 kg, and (BMI) between 19.0 and 26.0 kg/m² (inclusive); BMI = weight (kg) / height² (m²).
  4. Subjects are able to communicate effectively with the investigators and can understand and comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to methylconalamin injection, methylconalamin injection, or any component of the formulations, or history of (e.g., rash, urticaria).
  2. History of diseases or any other medical or physiological condition that could interfere with study results, including but not limited to disorders of the hematologic, cardiovascular, digestive, urinary, respiratory, nervous, immune, or endocrine systems, , psychiatric disorders, or metabolic abnormalities.
  3. History of significant bleeding tendency, coagulation disorders, systemic bleeding, neutropenia, or thrombocytopenia.
  4. Vaccination with any vaccine or within 1 month prior to dosing, or planned vaccination during the study.
  5. Consumption within 48 hours prior to dosing of foods or beverages that may affect metabolism (e.g., grapefruit, pomelo, mango, orange), alcohol, purine-rich or caffeine-containing foods/beverages (e.g., coffee, strong tea, chocolate), or foods rich in vitamin B12 (e.g., animal liver such as pork, beef, chicken, and shellfish such as oysters or clams).
  6. Daily excessive consumption of tea, coffee, and/or caffeine-containing beverages (≥8 cups per day, 1 cup = 250 mL) within 3 months prior to screening.
  7. Use of any drugs that affect liver enzyme activity within 30 days prior to first dose (e.g., enzyme inducers such as barbiturates, carbamazepine, phenytoin, dexamethasone; inhibitors such as SSRIs, ciprofloxacin, diltiazem, macrolides, metronidazole, ketoconazole, verapamil, fluoroquinolones).
  8. Use of any medication (prescription, over-the-counter, herbal, vitamin, or dietary supplement) within 2 weeks prior to screening, except for topical medications or eye drops with local effects.
  9. Weekly alcohol consumption exceeding 14 units within 3 months prior to screening (1 unit ≈ 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine), or positive alcohol breath test, or inability to abstain from alcohol during the study.
  10. Smoking ≥5 cigarettes/day within 3 months prior to screening, or inability to stop tobacco use during the study, or positive nicotine test.
  11. History of substance abuse within 3 months prior to screening, or positive drug screening.
  12. Blood donation or significant blood loss (≥400 mL), transfusion, or use of blood products within 3 months prior to screening, or planned blood donation during the study or within 3 months after study completion.
  13. History of surgery within 3 months prior to screening, planned surgery during the study, or history of surgery that may affect drug absorption, distribution, metabolism, or excretion.
  14. Use of any drug or participation in any drug/device clinical trial within 3 months prior to screening.
  15. Clinically significant abnormalities in vital signs, physical examination, laboratory tests (hematology, urinalysis, blood biochemistry, coagulation), chest X-ray, or 12-lead .
  16. Positive test for surface antigen (HBsAg), antibody (HCV-Ab), syphilis antibody (anti-TP), or antibody (anti-HIV).
  17. Subjects with special dietary requirements unable to comply with standardized study diet.
  18. Subjects unable to tolerate venipuncture or with difficult venous access, or history of orthostatic hypotension, syncope, or needle phobia.
  19. Male (or their partner) or female subjects planning pregnancy, egg/sperm donation, unwilling to use effective , positive pregnancy test, or lactating females from signing consent to 1 month after last dose.
  20. Subjects deemed unsuitable for participation by their own reason or at the investigator's discretion.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Group A

    Drug: Methylconalamin Injection(WP205) · Drug: Methylconalamin for Injection

  • Active comparator
    Group B

    Drug: Methylconalamin Injection(WP205) · Drug: Methylconalamin for Injection

Interventions

  • DrugMethylconalamin Injection(WP205)

    25 mg intramuscular injection in the upper-arm deltoid

  • DrugMethylconalamin for Injection

    25 mg intramuscular injection in the upper-arm deltoid

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    Time frame: 0 to 24 hours after each single intramuscular dose

  2. Area under the plasma concentration versus time curve (AUC)0-t

    Time frame: 0 to 24 hours after each single intramuscular dose

  3. Area under the plasma concentration versus time curve (AUC)0-∞

    Time frame: 0 to 24 hours after each single intramuscular dose

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events, Changes in Vital Signs, Physical Examinations, 12-lead ECG and Clinical Laboratory Tests [Safety]

    Assess safety through evaluation of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), physical examination findings, vital signs, 12-lead electrocardiogram parameters, and clinical laboratory test results.

    Time frame: 7 days

07

Study locations

1 site
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Sep 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 5, 2025
StartActual
Sep 10, 2025
Primary completionActual
Sep 18, 2025
CompletionActual
Sep 29, 2025
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07158099
Lead sponsor
Wanbangde Pharmaceutical Group Co., LTD
Responsible party
Sponsor
First posted
Sep 5, 2025
Start date
Sep 10, 2025
Primary completion
Sep 18, 2025
Completion
Sep 29, 2025
Last update
Aug 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion